Hospital Acquired Disease Testing Market By Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others) and By Region (North America, Europe, Asia Pacific, Middle East, Latin America, and Africa) - Trends, Analysis and Forecast till 2030

Hospital Acquired Disease Testing Market accounted for US$ 7.2 billion in 2020 and is estimated to be US$ 14.91 billion by 2030 and is anticipated to register a CAGR of 7.6%.

Hospital-acquired infections (HIA) are caused due to viral, bacterial, and fungal pathogens. Infection developed at a certain location such as hospitals due to presence of toxins is called as nosocomial infection or hospital acquired infections. Patients with compromised immune systems are at high risk of developing infection during their hospital stays. Infection can occur by several modes, which include healthcare staff, contaminated medical equipment, bed linens or air droplets. Also, infection can originate from the outside environment, another infected patient, staff that may be infected with unknown pathogen. Hospital acquired infections could be catheter-related bloodstream infection, surgical site infection, ventilator-associated pneumonia, and catheter-associated urinary tract infection.

Improper infection control practices and procedures at healthcare center and unclean and non-sterile environmental surfaces lead to development of hospital acquired diseases, which is driving growth of the hospital acquired disease testing market. Furthermore, increasing antibiotic resistance due to adoption of advanced medical care results into development of hospital acquired diseases, which in turn is fueling growth of the market. Moreover, increasing prevalence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopedic, and acute surgical ward are driving growth of the market.

Hospital acquired infection is a major burden for society, patients, and healthcare management. Increasing awareness among population regarding hospital acquired infections, adoption of infection control programs by healthcare facilities, maintaining personal hygiene by the hospital staff, complete sterilization of medical equipment, and a clean sanitary environment in the health care facilities may restrain growth of the hospital acquired disease testing market.

Hospital acquired disease testing market is segmented on the basis of test type and region. On the basis of test type, the market is segmented into urinary tract infection, surgical site infection, pneumonia, blood stream infection, methicillin-resistant staphylococcus aureus, and others.

Regional Insights:                                     

On the basis of region, the plant stem cells market finds its scope in North America, Europe, Latin America, Asia Pacific, Middle East and Africa. India hospital acquired infection diagnostics market is predicted to rise significantly due to rising occurrence of nosocomial illnesses such as surgical site infections and bloodstream infections. After completing a study on 10,835 patients in diverse clinical settings, India observed a 4.4 percent overall growth rate for hospital acquired illnesses, according to the Indian Journal of Basic and Applied Medical Research.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the

Hospital Acquired Disease Testing Market report based on Test Type and Region.

Hospital Acquired Disease Testing Market, By Region:

• North America

• U.S.
• Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the hospital acquired disease testing market include Diatherix laboratories, Life technologies, Cantel Medical Corporation Meridian Biosciences, Qiagen GmbH, Nordion, Roche, and Cepheid.

• Diatherix laboratories
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Life technologies
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Cantel Medical Corporation Meridian Biosciences
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Qiagen GmbH
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Nordion
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Cepheid
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies